Last reviewed · How we verify
NCT04209881
Ovarian Reserve and Ankylosing Spondylitis
trial testing ovarian reserve for Ankylosing spondylitis and control groups in Ovarian Diseases in 50 participants. Completed in 19 May 2020.
19 May 2020
Quick facts
| Lead sponsor | Kanuni Sultan Suleyman Training and Research Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 50 |
| Start date | 19 December 2019 |
| Primary completion | 19 May 2020 |
| Estimated completion | 19 May 2020 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- ovarian reserve for Ankylosing spondylitis and control groups
Conditions studied
- Ovarian Diseases — all drugs for Ovarian Diseases →
- Ankylosing Spondylitis — all drugs for Ankylosing Spondylitis →
- Anti-Mullerian Hormone Deficiency — all drugs for Anti-Mullerian Hormone Deficiency →
Sponsor
Kanuni Sultan Suleyman Training and Research Hospital
Who can join
Adults 18 to 45, female only, with Ovarian Diseases or Ankylosing Spondylitis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this study was to determine the status of ovarian reserve in patients with ankylosing spondylitis (AS) using anti-mullerian hormone (AMH) level and antral follicle count (AFC). Women with AS and women controls diagnosed according to the classification criteria proposed by the American-European Consensus Group will be included in the study. Ovarian reserve will be evaluated in terms of clinical findings, AFC and serum AMH and reproductive hormone levels. Researchers predict that the ovarian reserve may be reduced in patients with AS due to the autoimmune process and the pathophysiology of the disease. Serum AMH and ovarian AFC may be useful for assessing ovarian reserve. It is aimed to determine the course of ovarian reserve abnormalities and the best possible biomarkers of reduced ovarian reserve in patients with AS.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Ovarian reserve in patients with ankylosing spondylitis.
Yalçın Bahat P, Kadiroğulları P, Topbas Selcuki NF, Yücel B, et al · · 2021 · cited 8× · PMID 33030584 · DOI 10.1007/s00404-020-05824-8
Verify or expand the search:
- PubMed search for NCT04209881
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Ovarian Diseases
Currently open trials in the same condition.
- NCT05753826 — Adebrelimab Combined With Fuzuloparib in the Treatment of Patients With Recurrent Platinum-resistant Ovarian Cancer. · Phase 2 · recruiting
- NCT04807166 — Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer · Phase 2 · active not recruiting
Other Kanuni Sultan Suleyman Training and Research Hospital trials
Trials by the same sponsor.
- NCT07519551 — Serum Myostatin and Irisin Levels in Postmenopausal Women: Association With Bone Mineral Density and Muscle Strength · not yet recruiting
- NCT07480330 — Serum Neurofilament Light Chain Levels and Neuropathy Severity in Diabetic Polyneuropathy · not yet recruiting
- NCT07425405 — Daily Screen Exposure and Preoperative Anxiety in Children Aged 2-5 Years · recruiting
- NCT07358754 — The Relationship Between Serum S100B and Brain-Derived Neurotrophic Factor · recruiting
- NCT07261436 — Performance Comparison of Large Language Models in TAP Block Ultrasound Interpretation · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04209881 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Kanuni Sultan Suleyman Training and Research Hospital
- Last refreshed: 22 May 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04209881.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing